

## Availability of the 2024 Universal Registration Document

**Bordeaux, April 29, 2025 – 6:00 p.m. CEST – Aelis Farma** (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB<sub>1</sub> receptor, today announces the publication of its 2024 Universal Registration Document (URD) as filed with the French Financial Markets Authority (*Autorité des Marchés Financiers* (AMF)) on April 28, 2025, under number D.25-0314.

The Universal Registration Document 2024 includes in particular:

- The 2024 annual financial report;
- The statutory auditor's reports;
- Information on the statutory auditor's fees;
- Information relating to corporate social responsibility.

The URD can be consulted and downloaded on the Company's website under the heading [Investors / Documentation](#), as well as on the AMF website (<https://www.amf-france.org>).

### Financial Agenda:

- Annual General Meeting, May 27, 2025
- 2025 Half-Year Results, September 22, 2025

\*\*\*

### About AELIS FARMA

Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB<sub>1</sub> receptor of the endocannabinoid system (CB<sub>1</sub>-SSi). CB<sub>1</sub>-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB<sub>1</sub> hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB<sub>1</sub>-SSi appear to selectively inhibit the disease-related activity of the CB<sub>1</sub> receptor without disrupting its normal physiological activity. CB<sub>1</sub>-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.

Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB<sub>1</sub>-SSi in humans. The Company also has a portfolio of new innovative CB<sub>1</sub>-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB<sub>1</sub> receptor, including diseases involving peripheral organs, such as obesity and related

metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB<sub>1</sub>-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB<sub>1</sub> receptor and guaranteeing that the different compounds are not substitutable one with the others.

Aelis Farma draws on the talents of more than 25 highly qualified employees.

For more information, visit [www.aelisfarma.com](http://www.aelisfarma.com) and follow us on [LinkedIn](#) and [Twitter](#).



ISIN: FR0014007ZB4

Ticker: AELIS

B Compartment of Euronext Paris

## Contacts

### AELIS FARMA

Pier Vincenzo Piazza  
Chief Executive Officer  
[contact@aelisfarma.com](mailto:contact@aelisfarma.com)

### NewCap

Dusan Oresansky / Aurélie Manavarere  
Investor Relations  
[aelis@newcap.eu](mailto:aelis@newcap.eu)  
+33 1 44 71 94 92

### NewCap

Arthur Rouillé  
Media Relations  
[aelis@newcap.eu](mailto:aelis@newcap.eu)  
+33 1 44 71 00 15

## Disclaimer

### Forward-looking statements

Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document approved by the *Autorité des Marchés Financiers* on April 28, 2025, under number D.25-0314.

These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.